STUDIES OF CO-INFECTION OF MALARIA AND HEPATITES B AMONG PATIENTS ATTENDING INNOVATIVE BIOTECH KEFFI, NIGERIA

Malaria has been described as entirely preventable and treatable blood-borne mosquitos’ transmittable disease. However, despite continuous global efforts at all levels of health care to achieve global control, it still remains endemic in tropical and subtropical region, though with decreasing trend (WHO, 2012; 2013). Co-infections are becoming common risk factors that may contribute to the increased burden of morbidity in Patience. The aim of this study was to assess co-infections of malaria, hepatitis B (HBV), conducted at innovative Biotech Keffi, Nasarawa State, Nigeria, from June to August 2019. A total of 200 patients were examined for malaria and HBV status. A total prevalence of 25%, 44% and 12.5% for malaria, HBV and co-infection was recorded respectively. For both sexes, age group between30 to 39 had the highest prevalence for malaria, while 20-29 had the highest prevalence for HBV. Similarly, the age group between20 to 29 had the highest prevalence for co-infection of malaria and HBV. No prevalence was recorded in age group ≤ 9 in male for malaria, HBV and co-infection. The results indicated that there was no significant difference between patients in relation to sex (P˃0.05). It was concluded that co-infection of malaria and HBV had effect with varying immunity in relation to age. In view of these findings, further studies involving large samples are recommended